We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Drug/Biotech Stock Q2 Earnings Due on Aug 11: VIR and AUPH
Read MoreHide Full Article
It has been a mixed second-quarter earnings season for the drug/biotech stocks. Most companies beat estimates for earnings while missing the same for sales. However, AstraZeneca (AZN - Free Report) , Regeneron (REGN - Free Report) , Bristol-Myers, Vertex Pharmaceuticals and AbbVie beat estimates on both counts. As expected, almost all companies witnessed a significant negative impact on their top line due to business disruption and reduced doctor visits in the United States amid COVID-19-related mobility restrictions & limitations. Coronavirus-related stockpiling benefits, which had increased sales of several medicines in the first quarter, reversed in the second quarter and hurt sales. Lower selling, general and administrative costs due to COVID-19 related restrictions on travel and promotional activities gave a boost to earnings.
Per the Earnings Trends report as of Aug 5, 79.6% of the companies in the Medical sector, constituting nearly 84.3% of the sector’s market capitalization, have already reported earnings. While 86% beat earnings estimates, 79.1% beat the same for sales. Earnings are up 4.4% year over year while revenues are up 4%. Overall, second-quarter earnings for the Medical sector, comprising pharma/biotech and medical device companies, are expected to rise 1.9% on 3.4% sales increase
Let’s analyze two small biotech companies that are set to report second-quarter 2020 results on Aug 11.
Vir Biotechnology missed earnings estimates thrice in the three quarters that it has reported since its IPO in October 2019. Its average three-quarter negative earnings surprise is 201.4%.
Per our proven model, stocks with the combination of a positive Earnings ESP and a Zacks Rank #1, #2 (Buy) or #3 have a good chance of delivering an earnings beat. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
The Zacks Consensus Estimate stands at a loss of 62 cents per share.
On the conference call, investors will be keen to know about the progress of Vir Biotechnology’s investigational monoclonal antibodies, VIR-7831 and VIR-7832, which are being developed to treat the coronavirus disease, COVID-19.
This Victoria, Canada based clinical stage biotech has an Earnings ESP of 0.00% and a Zacks Rank of 3. The Zacks Consensus Estimate for the second quarter is pegged at a loss of 23 cents per share.
In the trailing four quarters, Aurinia beat estimates in only one quarter while missing in the other three with the average negative earnings surprise being 9.24%.
Aurinia Pharmaceuticals Inc Price and EPS Surprise
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce ""the world's first trillionaires,"" but that should still leave plenty of money for regular investors who make the right trades early.
Image: Bigstock
Drug/Biotech Stock Q2 Earnings Due on Aug 11: VIR and AUPH
It has been a mixed second-quarter earnings season for the drug/biotech stocks. Most companies beat estimates for earnings while missing the same for sales. However, AstraZeneca (AZN - Free Report) , Regeneron (REGN - Free Report) , Bristol-Myers, Vertex Pharmaceuticals and AbbVie beat estimates on both counts. As expected, almost all companies witnessed a significant negative impact on their top line due to business disruption and reduced doctor visits in the United States amid COVID-19-related mobility restrictions & limitations. Coronavirus-related stockpiling benefits, which had increased sales of several medicines in the first quarter, reversed in the second quarter and hurt sales. Lower selling, general and administrative costs due to COVID-19 related restrictions on travel and promotional activities gave a boost to earnings.
Per the Earnings Trends report as of Aug 5, 79.6% of the companies in the Medical sector, constituting nearly 84.3% of the sector’s market capitalization, have already reported earnings. While 86% beat earnings estimates, 79.1% beat the same for sales. Earnings are up 4.4% year over year while revenues are up 4%. Overall, second-quarter earnings for the Medical sector, comprising pharma/biotech and medical device companies, are expected to rise 1.9% on 3.4% sales increase
Let’s analyze two small biotech companies that are set to report second-quarter 2020 results on Aug 11.
Vir Biotechnology (VIR - Free Report)
Vir Biotechnology missed earnings estimates thrice in the three quarters that it has reported since its IPO in October 2019. Its average three-quarter negative earnings surprise is 201.4%.
Vir Biotechnology, Inc. Price and EPS Surprise
Vir Biotechnology, Inc. price-eps-surprise | Vir Biotechnology, Inc. Quote
Vir Biotechnology has an Earnings ESP of 0.00% and a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Per our proven model, stocks with the combination of a positive Earnings ESP and a Zacks Rank #1, #2 (Buy) or #3 have a good chance of delivering an earnings beat. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
The Zacks Consensus Estimate stands at a loss of 62 cents per share.
On the conference call, investors will be keen to know about the progress of Vir Biotechnology’s investigational monoclonal antibodies, VIR-7831 and VIR-7832, which are being developed to treat the coronavirus disease, COVID-19.
Aurinia Pharmaceuticals (AUPH - Free Report)
This Victoria, Canada based clinical stage biotech has an Earnings ESP of 0.00% and a Zacks Rank of 3. The Zacks Consensus Estimate for the second quarter is pegged at a loss of 23 cents per share.
In the trailing four quarters, Aurinia beat estimates in only one quarter while missing in the other three with the average negative earnings surprise being 9.24%.
Aurinia Pharmaceuticals Inc Price and EPS Surprise
Aurinia Pharmaceuticals Inc price-eps-surprise | Aurinia Pharmaceuticals Inc Quote
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce ""the world's first trillionaires,"" but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>